Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 3Melanoma 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Virus Diseases 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Pain 1Neuroectodermal Tumors 1Neuroblastoma 1Nervous System Diseases 1Neoplasms, Neuroepithelial 1Neoplasms, Nerve Tissue 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Insulin-Like Growth Factor I, Resistance To 1Humoral Hypercalcemia Of Malignancy 1Gliosarcoma 1Glioma 1Glioblastoma 1Epstein-Barr Virus Infections 1Disease 1

Interventions

ganitumab 23-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 2dalotuzumab 1conatumumab 1cixutumumab 1Sorafenib 1Receptor Protein-Tyrosine Kinases 1Paclitaxel 1Lapatinib 1Istiratumab 1Cisplatin 1Capecitabine 1BIIB022 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Insulin-Like Growth Factor I, Resistance To × Antibodies, Monoclonal × Clear all
NCT00956436 2013-09-16

Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)

Biogen

Phase 1 Completed
40 enrolled
Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡